Loading...
Loading...
OCX| Name | Value |
|---|---|
| Revenues | 104.0K |
| Cost of Revenue | 334.5K |
| Gross Profit | -230.5K |
| Operating Expense | 5,432.5K |
| Operating I/L | -5,663.0K |
| Other Income/Expense | 1,133.0K |
| Interest Income | 0.0K |
| Pretax | -4,530.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,530.0K |
OncoCyte Corporation is a molecular diagnostics company that specializes in developing and commercializing proprietary laboratory-developed tests for cancer detection. The company's main products include DetermaRx, a molecular test for early-stage lung adenocarcinoma, and DetermaIO, a proprietary gene expression assay. Additionally, OncoCyte provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company generates revenue through the sale of its diagnostic tests and services, as well as through collaboration agreements with other companies in the development and commercialization of molecular assays.
